Targeting Glycosylation Pathways and the Cell Cycle: Sugar-Dependent Activity of Butyrate-Carbohydrate Cancer Prodrugs

Chemistry and Biology

Volumn 13, Issue 12, 2006, Pages 1265-1275

  Sampathkumar, Srinivasa Gopalan ^a   Jones, Mark B ^a   Meledeo, M Adam ^a   Campbell, Christopher T ^a   Choi, Sean S ^a   Hida, Kaoru ^a   Gomutputra, Prasra ^a   Sheh, Anthony ^a   Gilmartin, Tim ^b   Head, Steven R ^b   Yarema, Kevin J ^a  

^a Johns Hopkins University   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID DERIVATIVE; HEXOSAMINE; N ACETYLMANNOSAMINE; N-ACETYLMANNOSAMINE; PRODRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; GLYCOSYLATION; HELA CELL; HUMAN; LEUKEMIA CELL LINE; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BUTYRATES; CELL CYCLE; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; GLYCOSYLATION; HELA CELLS; HEXOSAMINES; HUMANS; JURKAT CELLS; MOLECULAR STRUCTURE; PRODRUGS; SIGNAL TRANSDUCTION;

EID: 33845518649     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2006.09.016     Document Type: Article

References (63)

1. Møller M.B. Molecular control of the cell cycle in cancer: biological and clinical aspects. Dan. Med. Bull. 50 (2003) 118-138
2. Dube D.H., and Bertozzi C.R. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. 4 (2005) 477-488
3. Fuster M.M., and Esko J.D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 5 (2005) 526-542
4. Kelly W.K., and Marks P.A. Drug insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydoxamic acid. Nat. Clin. Pract. Oncol. 2 (2005) 150-157
5. Davie J.R. Inhibition of histone deacetylase activity by butyrate. J. Nutr. 133 (2003) 2485S-2493S
6. Dashwood R.H., Myzak M.C., and Ho E. Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?. Carcinogenesis 27 (2006) 344-349
7. Drummond D.C., Noble C.O., Kirpotin D.B., Guo Z., Scott G.K., and Benz C.C. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 495-528
8. Monneret C. Histone deacetylase inhibitors. Eur. J. Med. Chem. 40 (2005) 1-13
9. Miller S.J. Cellular and physiological effects of short-chain fatty acids. Mini Rev. Med. Chem. 4 (2004) 839-845
10. Papeleu P., Vanhaecke T., Elaut G., Vinken M., Henkens T., Snykers S., and Rogiers V. Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance?. Crit. Rev. Toxicol. 35 (2005) 363-378
11. Novogrodsky A., Dvir A., Ravid A., Shkolnik T., Stenzel K.H., Rubin A.L., and Zaizov R. Effect of polar organic compounds on leukemic cells: butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer 51 (1983) 9-14
12. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., and Pavletich N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999) 188-193
13. Rubenstein R.C., and Zeitlin P.L. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am. J. Respir. Crit. Care Med. 157 (1998) 484-490
14. Burlina A.B., Ogier H., Korall H., and Trefz F.K. Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients. Mol. Genet. Metab. 72 (2001) 351-355
15. Roomans G.M. Pharmacological approaches to correcting the ion transport defect in cystic fibrosis. Am. J. Respir. Med. 2 (2003) 413-431
16. Kasumov T., Brunengraber L.L., Comte B., Puchowicz M.A., Jobbins K., Thomas K., David F., Kinman R., Wehrli S., Dahms W., et al. New secondary metabolites of phenylbutyrate in humans and rats. Drug Metab. Dispos. 32 (2004) 10-19
17. Patnaik A., Rowinsky E.K., Villalona M.A., Hammond L.A., Britten C.D., Siu L.L., Goetz A., Felton S.A., Burton S., Valone F.H., et al. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res. 8 (2002) 2142-2148
18. Reid T., Valone F.H., Lipera W., Irwin D., Paroly W., Natale R., Sreedharan S., Keer H., Lum B., Scappaticci F., et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 45 (2004) 381-386
19. Edelman M.J., Bauer K., Khanwani S., Tait N., Trepel J., Karp J., Nemieboka N., Chung E.-J., and Van Echo D. Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug. Cancer Chemother. Pharmacol. 51 (2003) 439-444
20. Böhmig G.A., Krieger P.-M., Säemann M.D., Ullrich R., Karimi H., Wekerle T., Mühlbacher F., and Zlabinger G.J. Stable prodrugs of N-butyric acid: suppression of T cell alloresponses in vitro and prolongation of heart allograft survival in a fully allogeneic rat strain combination. Transpl. Immunol. 7 (1999) 221-227
21. Pouillart P., Ronco G., Cerutti I., Trouvin J.H., Pieri F., and Villa P. Pharmacokinetic studies of N-butyric acid mono- and polyesters derived from monosaccharides. J. Pharm. Sci. 81 (1992) 241-244
22. Pouillart P., Douillet O., Scappini B., Gozzini A., Santini V., Grossi A., Pagliai G., Strippoli P., Rigacci L., Ronco G., et al. Regioselective synthesis and biological profiling of butyric and phenylalkylcarboxylic esters derivated from d-mannose and xylitol: influence of alkyl chain length on acute toxicity. Eur. J. Pharm. Sci. 7 (1999) 93-106
23. Corfield A.P., Myerscough N., Gough M., Brockhausen I., Schauer R., and Paraskeva C. Glycosylation patterns of mucins in colonic disease. Biochem. Soc. Trans. 23 (1995) 840-845
24. Sell S. Cancer-associated carbohydrates identified by monoclonal antibodies. Hum. Pathol. 21 (1990) 1003-1019
25. Kobata A., and Amano J. Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours. Immunol. Cell Biol. 83 (2005) 429-439
26. Hadfield A.F., Mella S.L., and Sartorelli A.C. N-acetyl-d-mannosamine analogues as potential inhibitors of sialic acid biosynthesis. J. Pharm. Sci. 72 (1983) 748-751
27. Deshpande P.P., and Danishefsky S.J. Total synthesis of the potential anticancer vaccine KH-1 adenocarcinoma antigen. Nature 387 (1997) 164-166
28. Krug L.M. Vaccine therapy for small cell lung cancer. Semin. Oncol. 31 (2004) 112-116
29. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 491 (2001) 369-402
30. Chen H., Wang Z., Sun Z., Kim E.J., and Yarema K.J. Mammalian glycosylation: an overview of carbohydrate biosynthesis. In: Yarema K.J. (Ed). Handbook of Carbohydrate Engineering. (2005), Francis & Taylor/CRC Press, Boca Raton, FL 1-48
31. Hanisch F.G. O-glycosylation of the mucin type. Biol. Chem. 382 (2001) 143-149
32. Chou T.Y., and Hart G.W. O-linked N-acetylglucosamine and cancer: messages from the glycosylation of c-Myc. Adv. Exp. Med. Biol. 491 (2001) 413-418
33. Kim Y.S., Gum J., and Brockhausen I. Mucin glycoproteins in neoplasia. Glycoconj. J. 13 (1996) 693-707
34. Hang H.C., and Bertozzi C.R. The chemistry and biology of mucin-type O-linked glycosylation. Bioorg. Med. Chem. 13 (2005) 5021-5034
35. Keppler O.T., Horstkorte R., Pawlita M., Schmidt C., and Reutter W. Biochemical engineering of the N-acyl side chain of sialic acid: biological implications. Glycobiology 11 (2001) 11R-18R
36. Goon S., and Bertozzi C.R. Metabolic substrate engineering as a tool for glycobiology. J. Carbohydr. Chem. 21 (2002) 943-977
37. Jones M.B., Teng H., Rhee J.K., Baskaran G., Lahar N., and Yarema K.J. Characterization of the cellular uptake and metabolic conversion of acetylated N-acetylmannosamine (ManNAc) analogues to sialic acids. Biotechnol. Bioeng. 85 (2004) 394-405
38. Ghosh P., Ender I., and Hale E.A. Long-term ethanol consumption selectively inpairs ganglioside pathway in rat brain. Alcohol. Clin. Exp. Res. 22 (1998) 1220-1226
39. Suzuki O., Nozawa Y., and Abe M. Sialic acids linked to glycoconjugates of Fas regulate the caspase-9-dependent and mitochondria-mediated pathway of Fas-induced apoptosis in Jurkat T cell lymphoma. Int. J. Oncol. 23 (2003) 769-774
40. Eda S., Yamanaka M., and Beppu M. Carbohydrate-mediated phagocytic recognition of early apoptotic cells undergoing transient capping of CD43 glycoprotein. J. Biol. Chem. 279 (2004) 5967-5974
41. Malisan F., and Testi R. GD3 in cellular ageing and apoptosis. Exp. Gerontol. 37 (2002) 1273-1282
42. Chen H.Y., and Varki A. O-acetylation of GD3: an enigmatic modification regulating apoptosis. J. Exp. Med. 196 (2002) 1529-1533
43. Malykh Y.N., Schauer R., and Shaw L. N-glycolylneuraminic acid in human tumours. Biochimie 83 (2001) 623-634
44. Kim E.J., Sampathkumar S.-G., Jones M.B., Rhee J.K., Baskaran G., and Yarema K.J. Characterization of the metabolic flux and apoptotic effects of O-hydroxyl- and N-acetylmannosamine (ManNAc) analogs in Jurkat (human T-lymphoma-derived) cells. J. Biol. Chem. 279 (2004) 18342-18352
45. Zachara N.E., O'Donnell N., Cheung W.D., Mercer J.J., Marth J.D., and Hart G.W. Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress: a survival response of mammalian cells. J. Biol. Chem. 279 (2004) 30133-30142
46. Fishman P.H., and Brady R.O. Biosynthesis and function of gangliosides. Science 194 (1976) 906-915
47. Sarkar A.K., Fritz T.A., Taylor W.H., and Esko J.D. Disaccharide uptake and priming in animal cells: inhibition of sialyl Lewis X by acetylated Gal β1,4GalcNAc β-O-naphthalenemethanol. Proc. Natl. Acad. Sci. USA 92 (1995) 3323-3327
48. Rosato R.R., Almenara J.A., Cartee L., Betts V., Chellappan S.P., and Grant S. The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Mol. Cancer Ther. 1 (2002) 253-266
49. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
50. Bai L., and Merchant J.L. Transcription factor ZBP-89 cooperates with histone acetyltransferase p300 during butyrate activation of p21(WAF1) transcription in human cells. J. Biol. Chem. 275 (2000) 30725-30733
51. Siddiqui R.A., Jenski L.J., Harvey K.A., Wiesehan J.D., Stillwell W., and Zaloga G.P. Cell-cycle arrest in Jurkat leukaemic cells: a possible role for docosahexaenoic acid. Biochem. J. 371 (2003) 621-629
52. Blagosklonny M.V., Robey R., Sackett D.L., Du L., Traganos F., Darzynkiewicz Z., Fojo T., and Bates S.E. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol. Cancer Ther. 2002 (2002) 937-941
53. Darzynkiewicz Z., Juan G., and Bedner E. Determining cell cycle stages by flow cytometry. In: Bonifacino J.S., Dasso M., and Harford J.B. (Eds). Current Protocols in Cell Biology (1999), John Wiley & Sons, New York 8.4.1-8.4.18
54. Kim E.J., Jones M.B., Rhee J.K., Sampathkumar S.-G., and Yarema K.J. Establishment of N-acetylmannosamine (ManNAc) analogue-resistant cell lines as improved hosts for sialic acid engineering applications. Biotechnol. Prog. 20 (2004) 1674-1682
55. Dancey J.E., and Chen H.X. Strategies for optimizing combinations of molecularly targeted anticancer drugs. Nat. Rev. Drug Discov. 5 (2006) 649-659
56. Luchansky S.J., Yarema K.J., Takahashi S., and Bertozzi C.R. GlcNAc 2-epimerase can serve a catabolic role in sialic acid metabolism. J. Biol. Chem. 278 (2003) 8036-8042
57. Wang Z., Sun Z., Li A.V., and Yarema K.J. Roles for GNE outside of sialic acid biosynthesis: modulation of sialyltransferase and BiP expression, GM3 and GD3 biosynthesis, proliferation and apoptosis, and ERK1/2 phosphorylation. J. Biol. Chem. 281 (2006) 27016-27028
58. Hara I., Miyake H., Hara S., Arakawa S., and Kamidono S. Sodium butyrate induces apoptosis in human renal cell carcinoma cells and synergistically enhances their sensitivity to anti-Fas-mediated cytotoxicity. Int. J. Oncol. 17 (2000) 1213-1218
59. Chopin V., Slomianny C., Hondermarck H., and Le Bourhis X. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Exp. Cell Res. 298 (2004) 560-573
60. Williams E.A., Coxhead J.M., and Mathers J.C. Anti-cancer effects of butyrate: use of micro-array technology to investigate mechanisms. Proc. Nutr. Soc. 62 (2003) 107-115
61. Comelli E.M., Head S.R., Gilmartin T., Whisenant T., Haslam S.M., North S.J., Wong N.-K., Kudo T., Narimatsu H., Esko J.D., et al. A focused microarray approach to functional glycomics: transcriptional regulation of the glycome. Glycobiology 16 (2006) 117-131
62. Scheppach W., and Weiler F. The butyrate story: old wine in new bottles?. Curr. Opin. Clin. Nutr. Metab. Care 7 (2004) 563-567
63. Jourdian G.W., Dean L., and Roseman S. The sialic acids: XI. A periodate-resorcinol method for the quantitative estimation of free sialic acids and their glycosides. J. Biol. Chem. 246 (1971) 430-435